The lack of wage growth has contributed to slower price gains.
Securities near the middle of the quality scale will probably be in a sweet spot when the Federal Reserve raises rates.
Fewer available properties, higher prices and still-tight credit are hurdles for some customers as first-time buyers remain reluctant to enter the market.
As bond trading has declined, so have the jobs, leaving even some of the most senior traders and salesmen moving from firm to firm.
Individual investors are plowing money back into the U.S. stock market just as professional strategists say gains for this year are over.
John C. Martin, the CEO of Gilead Sciences, has become a billionaire on the prospects of a powerful new hepatitis C drug that’s attracting scrutiny over its $1,000 per pill price tag.